Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH Trial): a National Multi-center, Retrospective-prospective, Cohort Study

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Observational
SUMMARY

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Age \>18 years old.

• The diagnosis of cardiomyopathy was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.

• Patients or their families agreed to participate in the study and authorized informed consent.

Locations
Other Locations
China
First Affiliated Hospital of Xi'an Jiantong University
RECRUITING
Xi'an
Contact Information
Primary
Yang Yan
yangyan3@xjtu.edu.cn
+862985323869
Backup
Guoliang Li
liguoliang_med@163.com
+862985323869
Time Frame
Start Date: 2024-05-09
Estimated Completion Date: 2032-08-31
Participants
Target number of participants: 500
Treatments
HCM group
Patients were diagnosed with HCM.
DCM group
Patients were diagnosed with DCM.
ARVC group
Patients were diagnosed with ARVC.
NDLVC group
Patients were diagnosed with NDLVC.
RCM group
Patients were diagnosed with RCM.
LVNC group
Patients were diagnosed with LNVC.
Sponsors
Leads: First Affiliated Hospital Xi'an Jiaotong University

This content was sourced from clinicaltrials.gov